18F-AV-1451 Autopsy Study

A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology

This study is designed to test the relationship between ante-mortem flortaucipir Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.

Inclusion Criteria:

• Have a projected life expectancy of ≤ 6 months
• Can tolerate a 20 minute PET scan
• Give informed consent or have a legally authorized representative to consent for study procedures and brain donation consistent with the legal requirements of the State in which they die

Exclusion Criteria:

• Aggressively being treated with life sustaining measures
• Known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment
• Clinically significant infectious disease
• Currently receiving any investigational medications except with permission from the study sponsor
• Participated in an experimental study with an amyloid or tau targeting agent
• Suspected encephalopathy due to alcoholism or end-stage liver disease
• Females of childbearing potential
• History of risk factors for Torsades de Pointes or are currently taking medication known to cause QT prolongation